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A PILOT STUDY: PIRFENDIONE, 8% (KITOSCELL)  
AS A TREATMENT FOR STRIAE DISTENSAE 
JEREMY PARCO KOONTZ 
ABSTRACT 
 Striae distensae (SD; stretch marks) are well-recognized skin lesions that occur in 
a large percentage of the population. Although they rarely cause significant medical 
concern, they can be a source of extreme physiological stress to affected patients. They 
occur commonly in pregnancy, puberty and obesity, but also become manifest following 
various medical conditions and therapeutic interventions. The precise etiological 
mechanism of SD has yet to be determined, however numerous theories have been 
proposed and risk factors have been identified.  To date, there are many different 
treatment modalities to improve size and color of striae including diet and exercise, 
topical and laser therapies and surgery but none have demonstrated a consistent 
effectiveness. This unmet medical need may be addressed by the use of Pirfenidone. 
Pirfenidone is a small synthetic non-peptide molecule of low molecular weight (185.2 
Daltons) that has been identified to have immuno-modulatory and anti-inflammatory 
properties. Clinical evidence indicates that Pirfenidone can modulate collagenase and 
fibroblastic activity by the modulation of cytokines in the wound healing process, such as 
TFG-β and TNF-α, which lead to effective collagen remodeling. Pirfenidone has 
exhibited low-toxicity in pre-clinical and clinical studies. These in vitro and in vivo 
findings suggest that Pirfenidone may be a safe and effective treatment of patients with 
SD. 
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INTRODUCTION 
 
Striae Distensae: Overview 
 Striae distensae (SD) are defined as atrophic linear dermal scarring with 
overlying epidermal atrophy (Bak et al., 2009; Yang & Lee, 2011). Striae most 
commonly occur on the abdomen, buttocks, thighs, upper arms, and breasts. They can 
have differing etiologies and characteristics and are found in both genders across all 
ethnic backgrounds. They occur frequently during adolescence or pregnancy when there 
is rapid tissue growth, influencing an estimated 90% of pregnant women, 70% of 
adolescent females, and 40% of adolescent male (Al-Himdani, Ud-Din, Gilmore, & 
Bayat, 2014). They occur in numerous other physiological and pathological conditions 
such as obesity, connective tissue disorders, Cushing’s syndrome, Marfan syndrome, 
hypercortisolism, diabetes, and long-term systemic or topical steroid use or exposure 
(Yang & Lee, 2011).  
Although striae are not usually a life-threatening medical problem, they have the 
potential to cause great emotional distress and serious health complications to patients. 
The highly pigmented, broadly distributed red/purple striae (striae rubra and striae 
caerulea) can persist for decades without change. Often seen in young cancer survivors 
and adolescents, these prominent scars can have a significant impact on quality of life 
(QOL). Children afflicted with striae were more susceptible to depression, loss of self-
esteem, emotional distress, eating disorders (Strumia, 2005), and in some cases, body 
dysmorphic disorder (Tedeschi, Dall’Oglio, Micali, Schwartz, & Janniger, 2007).  
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Patients may also face serious medical risks due to the ulceration of SD due to excessive 
stretching forces or the increased use of concurrent corticosteroid and bevacizumab 
therapy. In malignant glioma patients, there has been an increase in the incidence of 
ulcerated striae. Bevacizumab, used to treat glioma, is an anti-vascular endothelial growth 
factor (VEGF) antibody, which plays an important role in wound healing and collagen 
production (Peters et al., 2011). Patients with ulcerated striae are at a higher risk of 
infection. Thus, SD can have a significant negative impact on quality of life and can lead 
to an increased risk of secondary adverse events. 
 
Risk Factors and Etiology 
Although the exact cause of SD is unknown, many hypotheses have been 
proposed in the literature. As one of the earliest explanations for the cause of SD, in 1925 
Kogoj et al. suggested that the formation of SD was a direct result of toxic damage to 
tissue architecture from striatoxins (Gauglitz, Reinholz, Kaudewitz, Schauber, & 
Ruzicka, 2013). Some researchers argue that striae are a result of excessive mechanical 
stress applied to the dermis, resulting in damage to the connective tissue framework 
(Elsaie, Baumann, & Elsaaiee, 2009). The common name “stretch marks” comes from 
this belief.  For example, marks caused by tensional stress in pregnancy, adolescent 
growth spurts, and weight gain due to bodybuilding or obesity. However, others dispute 
this theory citing research that finds no correlation between abdominal girth in pregnant 
women and resulting striae (Elsaie et al., 2009).  It has also been suggested that striae 
develop more easily in skin that has a high proportion of rigid cross-linked collagen, as 
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occurs in early adult life (Shuster, 1979). Increased adrenal cortical activity has also been 
implicated in the formation of striae, as in the case of Cushing’s syndrome (Stevanović, 
1972). Corticosteroids can have catabolic effects on the activity of fibroblasts, resulting 
in inhibited collagen deposition and a decreased activity of extracellular matrix 
components (Tsuji & Sawabe, 1988). Striae are a common side effect of glucocorticoids 
(Schoepe et al. 2006), such as when they are used in the treatment of cancer. Though 
many similarities exist between the maturation of SD and that of normal wound healing, 
research to elucidate the definite pathogenesis of SD is ongoing, 
Clinically, the maturation of SD may occur in stages. First, the acute stage is 
characterized by flattened areas of pink-to-violaceous skin that form along Langer’s lines 
and may be slightly raised and itchy (Shuster, 1979). These lesions, or striae rubra, tend 
to be oriented perpendicularly to the direction of greatest tension and typically in areas of 
high adipose tissue deposition (Elsaie et al., 2009). Most of the time, the striae rubra 
change gradually to a blue-to-purpuric color during the sub-acute stage and are 
predisposed to increase in length, flatten and take on a smooth or finely wrinkled 
appearance. Over time, some highly-pigmented striae may evolve into a final stage, 
known as the chronic stage. In the chronic stage, the dark scars may fade in color and 
evolve into white atrophied depressions, or striae alba, generally several centimeters long 
and 1-10 mm wide.  
Although some striae may eventually fade to striae alba, there is no defined 
timeframe for this transformation. The darker color of earlier SD is likely due to the 
inflammatory response associated with the vasodilatation. Other forms of striae rubra are 
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striae caerulea (blue) and striae nigra (black). These denominations of deeply colored SD 
may appear darker than surrounding skin due to increased melanization (Hermanns & 
Piérard, 2006). For some patients, the maturation of striae rubra to striae alba can take 
months, while other patients experience scars that persist for decades without maturation. 
For the population of adolescents and young adult patients that are affected by the latter, 
striae can be the source of significant psychological stress and greatly influence quality of 
life.  
 
Histology and Pathophysiology of SD 
The histology and natural evolution of SD is similar to the process of wound 
healing and scar formation (Atwal et al. 2006). The normal wound healing process is both 
complex and highly orchestrated. This process is mediated in large by interacting 
molecular signals, primarily cytokines, which participate in the various stages of tissue 
reconstruction after injury: initiation (clotting), inflammation, migration/proliferation and 
remodeling.  
Initiation begins with vasoconstriction and platelet activation soon after injury. In 
areas where the damage to cellular architecture has resulted in vascular damage and 
hypoxia of adjacent tissue, platelets initiate the clotting cascade and release growth 
factors and cytokines to influence tissue edema and initiate inflammation. Some of these 
prominent growth factors include platelet-derived growth factor (PDGF), VEGF and the 
transforming growth factors-beta (TGF-β). VEGF is in part responsible for the 
extravasation of plasma proteins to create a temporary structure for cell migration to the 
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wound site and, along with PDGF, the process of angiogenesis, new blood vessel growth. 
The TGF-β family of cytokines is involved in the coordinating the wound-healing 
process from the initial insult and clot formation, to the final phase of matrix deposition 
and remodeling. TGF-βs are released in large quantities and have the most potent 
stimulatory effect on extracellular matrix deposition of any cytokine so far examined 
(Jacobsen, Ruscetti, Roberts, & Keller, 1993). Autocrine expression of TGF-β by 
leukocytes and fibroblasts leads to a cascade of additional cytokine release including 
tumor necrosis factor-alpha (TNF-α), interleukin-1-beta (IL-1β) and other chemokines 
(Wan et al., 2012). 
During the inflammation stage of healing, neutrophils, macrophages and 
lymphocytes infiltrate the wound site. These cells are attracted to the wound site by the 
cytokines released in the initiation stage. Neutrophils release cytoplasmic granules 
containing proteases that eliminate necrotic residues. Macrophages further aid the 
removal of bacteria and necrosis by engulfing offending debris. They also secrete growth 
factors for fibroplasia and angiogenesis. Finally, lymphocytes participate in the regulation 
of wound healing, although their role is less understood. 
The inflammation stage is followed by migration and proliferation. Cellular 
transformations such as wound closure, neovascularization, and re-epithelialization 
highlight this stage of wound healing. Endothelial cells participate in angiogenesis and 
the generation of a de novo network. Re-epithelialization is the hallmark process of 
proliferation. As early as 12 hours after injury, epidermal cells, responsible for 
maintenance of structural integrity of the dermis, develop pseudopods and lose their 
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intercellular adhesion leading to cell migration to the wound site. The epidermal cells 
proliferate quickly to ameliorate the epithelial deficit. Fibroblasts are guided by 
fibroblast-derived chemotactic factors to migrate to the wound margins. In addition to 
physical structure, fibroblasts have many other important functions. Their main role is the 
production of fundamental extracellular matrix components such as collagen, elastin, and 
proteoglycans. The process by which the fibroblastic recruitment and matrix synthesis are 
accomplished is coordinated in large part by signaling from TGF-β (Wahl, 1994). 
 Remodeling is a dynamic process in response to the biomechanical stress that the 
wound site experiences and may last for months following the injury. Over time, cell 
density increases and vascularization diminishes towards pre-injury levels. Also, tensile 
strength increases through the replacement of type III collagen, which is quickly 
deposited after the injury during the migration/proliferation stage, with type I collagen 
that is placed down in an orderly natural state during the remodeling stage. In normal 
collagen deposition, a balance is established between collagen synthesis and degradation. 
This process is accomplished through the actions of the fibroblasts and macrophages. The 
fibroblasts are involved in the synthesis of collagen, which is regulated at the 
transcriptional and translational level. Collagen degradation, performed by macrophages, 
is regulated by matrix metalloproteinases (MMPs) (Macías-Barragán et al., 2010). The 
MMP family of enzymes is predominately produced by macrophages and is capable of 
breaking down many components of the ECM for migration and tissue remodeling in 
wound healing. Tissue inhibitors of metalloproteinases (TIMPs) regulate MMPs. Shortly 
after injury, the amount of collagen deposition produced by the fibroblasts exceeds that 
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which is degraded. Yet, as the wound matures the level of collagen and extracellular 
matrix production and degradation become equal reaching a homeostatic equilibrium. 
 
Abnormal Histology and Pathophysiology of SD 
In comparison to the timely and tightly orchestrated reparative process of normal 
wound healing, the process of abnormal wound healing, like keloid scars and SD, is 
significantly altered. The resulting tissue architecture lacks anatomical and functional 
integrity. The disorganized structure may be a result of an attenuation or disruption of 
cellular and molecular signals from growth factor and cytokines released during the 
wound repair process.  In the case of keloid scars the rate of deposition of collagen at the 
wound site exceeds the rate collagen degradation. Conversely, in SD, the rate of collagen 
degradation exceeds that of collagen deposition. This change from equilibrium leads to 
the different pathologic outcomes. 
In early stages of striae development, skin elastolysis is followed by excessive 
mast cell degranulation leading to activated macrophages that envelop fragmented elastic 
and collagen fibers (Arem & Kischer, 1980). Inflammatory changes may predominate 
with edema around the dermal venules. In later stages, SD is characterized by the 
thinning of the overlying epidermis, diminished rete ridges and shallower dermal 
papillae. In common with fibrosis and scars, scanning electron microscopy of striae show 
dysfunction of the skin connective tissue yielding a formation of collagen fibers 
preferentially aligned in a single direction (De Pasquale et al., 1987). In SD, the collagen 
in the upper third of the dermis is layered in thin eosinophilic bundles oriented in straight 
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lines, parallel to the surface of the skin (Piérard et al., 1999). Contrarily, collagen in 
normal skin is interwoven in a meshwork distribution.  
Also, Watson et al. (1998) observed that the dermal elastic system shows 
breakage and retraction of the elastic fibers in the reticular dermis. This system allows the 
skin to spring back to its resting conformation after being distended. The elastic fibers in 
normal skin form a complex and intertwining system that forms a continuum of thick 
elastic fibers from the dermal-epidermal junction (DEJ) through the papillary dermis and 
to the reticular dermis. However in SD, the broken elastic fibers curl at the sides of the 
striae forming a characteristic pattern on scanning electron microscopy. SD have a 
statistically significant reduction in the number of vertically oriented elastin and fibrillin 
fibers proximal to the DEJ (Watson et al., 1998).  
Damage to the fibrous framework of SD has fueled research of the cellular 
interactions that mediate the balance between fibrous deposition and degradation and 
their influence on wound repair. In SD, damage to the fibrillin framework may induce 
additional TGF-β release and activation (Watson et al., 1998). Fibrillin—a component of 
elastic fibers—shares a signature eight cysteine TGF-β-binding protein-like (TB) domain 
with latent TGF-β-binding proteins and contains Arg-Gly-Asp (RGD) integrin binding 
domains (Robertson, Jensen, & Handford, 2011). The effects of TGF-βs are considered a 
link between the processes by which cells and tissues respond to infection or injury and 
initiate repair (Wahl, 1994). As stated previously, TGF-βs has complex and far-reaching 
effects in the process of wound repair. For example, TGF-βs acts as a conversion factor 
regulating repair by orchestrating the inflammatory response, inhibiting the response and 
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then converting to a response of matrix deposition. TGF-βs can recruit and activate 
leukocytes, namely the macrophages, in inflammation and tissue remodeling, but can also 
down-regulate these catabolic processes of this same populations of cells by inhibiting 
activated inflammatory cells and stimulating activity in fibroblasts for matrix synthesis. 
Thus, TGF-βs acts in a bi-directional manner (Jacobsen et al., 1993; Wahl, 1994). 
Chronic stimulation of TGF-βs, as is the case in SD, may lead to variations in wound 
healing control and lead to pathological diseases.  
It is no surprise that understanding the nature and effects of TGF-βs have drawn 
the interest of researchers aiming to modulate the wound healing process and alter SD 
pathology.  
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CURRENT TREATMENTS FOR STRIAE 
 
Despite the increasing knowledge of wound healing and collagen metabolism, 
treatment for SD remains disappointing and frustrating for patients. Several treatment 
modalities have been proposed for the treatment of striae but many are considered 
ineffective or do not offer complete resolution of the SD. 
 
Diet and Exercise 
Many people develop striae where weight gain is common; such areas include the 
abdomen, thighs, upper arms, hips and buttocks. Schwingel et al. examined the effect of 
exercise and weight loss on stretch marks. In this study, women between 24 and 53 years 
of age participated in a 3-month weight loss program. Participants were assigned into one 
of three groups; diet (n = 29), diet plus aerobic exercise program (n = 31), or diet plus 
resistance exercise program (n = 20). SD was prevalent in 79% of the participants. Study 
results demonstrated that the severity of striae did not change with weight loss, regardless 
of which study arm they were associated with. Although diet and exercise may slow 
down the progression of stretch marks and the likelihood of developing more striae, 
medical experts do not acknowledge them as an effective means of treating existing SD 
(Elsaie et al., 2009). 
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Topical Treatments 
A wide variety of topical treatments have been assessed as potential treatment 
options for SD ranging from easily attainable household products, such as cocoa butter, 
olive oil and castor oil, to synthetically produced agents. Yet to date, no treatment has 
shown consistent results at treating SD. A Cochrane review evaluated the use of 
prophylactic topical creams for the prevention and treatment of SD from six trials 
involving a total of 800 pregnant women (Brennan, Young, & Devane, 2012). No 
statistically significant difference was seen in the development of SD in women who 
received topical preparations with active ingredients compared to women who received a 
placebo or no treatment. Creams evaluated included alphastria, trofolastin, cocoa butter, 
olive oil and verum. Alphastria and trofolastin creams are thought to stimulate fibroblasts 
activity and have an antagonistic effect against glucocorticoids. The hyaluronic acid 
content in alphastria is thought to be its active ingredient. Verum is also composed of 
hyalurinolic acid, with vitamin E, panthenol, elastin and menthol (Elsaie et al., 2009). All 
were considered not effective. In a double-blind randomized controlled trial, Buchanan et 
al. (2010) showed no significant difference between patients developing SD in groups 
treated with cocoa butter or placebo. 
Other approaches include massage with or without comfrey, hypericum, maritime 
pine, equisetum, slippery elm, sweet almond oil, wheat germ oil, olive oil, avocado oil, 
castor oil, wheat grass or eucalyptus tree oil. These agents’ putative mode of action is 
hydration, meant to increase cellular volume and oppose mechanical atrophy. 
Moisturizers or emollients serve to make the external layers of the skin softer and more 
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pliable, by increasing the skins’ hydration or water content, and reducing evaporation.  
Unfortunately little in the literature is available to support the success of these creams or 
oils in striae prevention.  
Massage is frequently recommended to improve the aesthetic outcome of scars 
postoperatively. Regimens for how to implement massage vary greatly. Shin and 
Bordeaux (2012) reviewed studies including 144 patients who received scar massage, of 
variable frequencies and durations, and found that 90% had improved appearance or 
Patient Observer Scar Assessment Scale scores. Yet they also concluded that the 
evidence for the use of scar massage is weak with variable outcomes, which are not 
measured with objectivity or in any standardized manner. Specifically related to striae, 
there is no data to support massage as a treatment for SD.  
Another set of agents proposed to treat striae are chemical peels (Elsaie et al., 
2009). The mode of action of these agents is thought to involve fibroblastic stimulation, 
inhibition of glucocorticoids, or stimulation of collagen production/synthesis. Three 
different strengths of chemical peels exist: light, medium, and deep. Light chemical peels, 
including alphahydroxy acid (AHA) and glycolic acid, are usually applied in medical 
offices, with minimal discomfort, and no anesthetic necessary. Medium peels, such as 
trichloroacetic acid (TCA), are also applied in a medical office or ambulatory surgical 
center. Frequently these require a combination of tranquilizer and an oral analgesic 
(Halaas, 2004). Phenol is an example of a deep chemical peel. Administration of deep 
chemical peels typically require general anesthesia.  
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Topical tretinoin, a vitamin A derivative, is one of the first light chemical peels 
used to treat SD and has yielded variable results (Elson, 1990). In a small 22 patient study 
evaluating 0.1% tretinoin (n = 10) versus placebo (n = 12), the investigators reported a 
reduced length and width of 14% and 8% in treated lesions, compared to the increase of 
10% and 24% in placebo group. There was no significant difference in dermal collagen 
and elastic fibers in treatment compared to placebo (Kang et al., 1996). The creams were 
applied once a day for six months. Eight of the tretinoin treated patients had subjective 
improvement compared to one in the placebo group. No significant differences between 
the groups were found with histologic assessments. The same study showed improvement 
in the clinical appearance of striae in their ‘active’ phase, striae rubra, without much 
effect on striae alba. 
Glycolic acid (alpha hydroxyl acid) and TCA are thought to function by 
stimulating collagen synthesis. Various reports have claimed some efficacy from these 
agents with the peeling followed by hydration of skin (Crowther et al., 2008). There are 
various reports of the potential clinical effects of glycolic acid on rejuvenation, peeling 
and photoaging, but no data regarding prevention of or treatment for SD. Ash, et al 
(1998) compared topical treatment of striae alba with 20% glycolic acid/0.05% tretinoin 
and 20% glycolic acid/10% L-ascorbic acid utilizing daily applications of each for 12 
weeks. Both regimens showed improved appearance of striae and were safe in study 
patients with minimal irritation, although it was not determined which of the ingredients 
provided the observed effect. No significant differences between the groups were found 
with histologic assessments. 
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Laser Treatments 
The introduction of laser energy as a treatment modality for dermatologic diseases 
was first proposed by Anderson and Parrish (1981). This technique is characterized by 
the bombardment of a particular chromophore using short bursts of photoenergy 
(photons).  Specific wavelengths of light are used to preferentially target the desired 
chromophore, while leaving the neighboring tissue undisturbed to achieve localized 
photothermal injury. Lasers and light source treatments may produce energy that 
selectively targets oxyhemoglobin in the dilated vessels of immature SD or may induce 
changes in collagen and elastin formation (Savas, 2013). Despite the characterization and 
popularity of selective photolysis treatments, the exact mechanism by which lasers treat 
SD is largely unknown. 
Laser ablation is the process of removing and resurfacing skin by irradiating it 
with a targeted beam of light, either superficially or involving the deeper layers. Carbon 
dioxide laser resurfacing is thought to illicit fibroblast activity and epidermal 
vaporization and coagulation of the underlying dermis (Lee et al., 2010).  Initially, the 
predictable depth of tissue ablation and thermal denaturation and preliminary results of 
argon and carbon dioxide laser ablation seemed promising. Yang and Lee (2011) 
evaluated carbon dioxide laser resurfacing in 24 South Korean patients with varying 
degrees of striae alba. Patients were randomly stratified into a treatment protocol of 
nonablative Er:glass laser or ablative fractional carbon dioxide laser. Patients were 
treated three times over four-week treatment intervals. Although two patients were 
 15 
ultimately excluded during treatment due to pruritus and hyperpigmentation, the study 
authors stated that carbon dioxide laser resurfacing treatment may help to improve the 
appearance of striae alba in Asian skin. This treatment modality was not evaluated as an 
effective treatment of the more prominent striae rubra. 
Ablative laser treatments have many disadvantages. Treatments require pain 
management, carry the risk of adverse reactions, and ultimately have shown inconclusive 
results. Ablative laser treatment procedures require physician administered anesthesia, 
conscious sedation and other types of treatment for pain. Therefore, after ablative laser 
treatment the patient requires an intense post-operative care and recovery time, during 
which the skin granulates (i.e. scabs) and is shed. This process carries with it the potential 
of adverse events such as infection, poor wound healing and the risk of dyspigmentation, 
hyperpigmentation and scarring, particularly in the darker skin types. In the previous 
study, authors Yang and Lee cautioned patients with Fitzpatrick skin types IV to VI to 
avoid the use of carbon dioxide laser due to the probability of developing 
postinflammatory dyschromia. After treatment, patients have a period of transient mild 
erythema and hyperpigmentation and are required to avoid prolonged sun-exposure (Goel 
et al. 2011). Carbon dioxide and argon, both ablative laser modalities, were not shown to 
yield permanent results. The use of both laser treatments resulted in uniform scar 
reoccurrence (Alster, 1997).  
Nonablative lasers modalities, such as 585-nm flashlamp-pumped pulse dye laser 
(PDL), 308-nm xenon chloride (XeCl) excimer laser, 577-nm copper-bromide laser, 
1,450-nm diode laser and 1,064-nm neodymium-doped:yttrium-aluminum-garnet 
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(Nd:YAG), penetrate the skin, but without visible wounding. Theoretically, these laser 
treatments target the hemoglobin or melanin in SD.  
The 585-nm PDL is the most commonly used laser treatment for SD (Elsaie et al., 
2009). Researchers have attempted to target the dilated blood vessels in striae rubra with 
the 585-nm flashlamp PDL. Treatment is administered through a series of laser 
treatments done at lower energy levels, which minimizes the chances of burning, 
pigmentation, scarring and other unwanted side effects. McDaniel et al. (1996) evaluated 
the clinical improvement of SD in a controlled study of 39 patients with striae rubra. 
Patients were stratified into four treatment groups and treated with several courses of 
585-nm PDL using dynamic cooling on affected sites, including the abdomen, thighs and 
breasts. McDaniel determined the optimal energy density (3 J/cm2) and measured 
outcomes based on subjective analysis, shadow profilometry and histopathological 
analysis. When compared to untreated SD, outcomes demonstrated an increased amount 
of collagen and dermal elastin improving the surface topography. A limitation of this 
study was that the principle investigator was not blinded to the different treatment 
protocols when evaluating subjective analysis data throughout the study. Jiménez et al. 
(2003) also documented collagen changes in SD lesions in a controlled study of 20 
patients treated with 585-nm PDL. But, they found no statistically significant change in 
the SD area compared to controls. Changes were only moderately beneficial in reducing 
the degree of erythema in striae rubra of patients with skin types II to IV, noting also that 
there was no change in striae alba. They strongly cautioned against the use of PDL in 
patients with darker skin types, V to VI, citing the similarities between melanin and 
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hemoglobin as a chromophore for the light energy from the 585-nm PDL. Post-
inflammatory hyperpigmentation was experienced by this melanin-rich population even 
with low treatment fluences. It was determined that this treatment modality should be 
avoided or used with extreme caution. 
Technological advances have allowed the implementation of the 308-nm XeCl 
laser, an ultraviolet laser with characteristics close to that of ultraviolet B (UVB) light. 
The 308-nm XeCl laser has a good safety profile, greater precision and the ability to 
deliver a higher fluence in a shorter amount of time compared to previous laser 
treatments. Study results have shown pigment correction in some late-stage 
hypopigmented striae alba due to a proliferation and hypertrophy of melanocytes. 
Unfortunately, the repigmented changes declined back to baseline after 6-months and 
failed to show any improvement in skin atrophy. These results highlight the need for 
regular maintenance through repeated treatments, deeming the use of 308-nm XeCl laser 
as a temporary solution to a chronic problem. 
The 577-nm copper-bromide laser emits light energy coinciding with the 
maximum absorption peak of hemoglobin; however only one small 15-patient study has 
been published supporting that this is a safe, efficacious and potentially a long-term 
solution for SD treatment. Furthermore, study results show that it was only evaluated on a 
narrow sample of skin types, II and III, without histological information collected, 
making further research necessary (Longo, Postiglione, Marangoni, & Melato, 2003). 
 Similarly, there has been only one clinical study to substantiate any efficacy of 
the use of 1,450-nm diode laser as a treatment for SD. Using 1,450-nm diode laser with 
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cryogen cooling spray, Tay et al. treated 11 patients with SD and Fitzpatrick skin types 
IV to VI. Areas of treatment included the abdomen, arms, back, buttocks and thighs. 
When evaluated for safety and efficacy, 1,450-nm diode laser was deemed ineffective by 
physician assessment, showing no improvement in any lesions for all subjects after two 
months of treatment (Tay, Kwok, & Tan, 2006). Sixty-four percent of the patients (n = 7) 
also experienced transient erythema and significant postinflammatory hyperpigmentation 
following treatment. Based on these results, Tay el al. does not recommend the use of 
1,450-nm diode laser for treatment of SD in similar skin types. 
Nd:YAG laser was found to induce new collagen formation in a study evaluating  
treatment for facial wrinkles. Nd:YAG has a well-documented affinity for vascular 
targets. Due to these results, Goldman et al. (2008) conducted a small, single arm study 
targeting the dilated venules of immature SD in 20 patients with Fitzpatrick skin types of 
II to IV. Patients averaged 3.45 treatment sessions with a 3 to 6 week treatment interval. 
Results were described as excellent by fifty-five percent of study participants and only 
40% of doctors. Yet some patients (n = 4) experienced no change in SD appearance.  
The use of laser therapies for the treatment of SD, although popular, has been 
marred with uncontrolled studies and results that underscore their many limitations.. 
Laser studies are understandably difficult to blind, in addition a significant proportion of 
the studies had small sample sizes, limited patient diversity, and a lack of control groups 
and randomization. Laser treatments are costly and the degree of improvement seems to 
be minimal to moderate and transient with potential adverse events such as erythema, 
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hyperpigmentation, hypopigmentation, blistering and crusting, scarring, purpura, 
secondary infection, and pain (Handley, 2006).  
 
Other Treatments 
Other treatments, including microdermabrasions, surgical excision, subcision, 
grafting procedures, cryotherapy, corticosteroid injections, pressure therapy, and 
radiation therapy have all been investigated as treatments for SD. None have shown 
significant benefit. Oftentimes the side effects and resulting scars were as severe as the 
original SD (Alster & Handrick, 2000).  
Microdermabrasion is a skin resurfacing technique using inert aluminum oxide as 
an abrasive agent propelled at irregularities in the skin surface irregularities. 
Microdermabrasion has been thought to set in motion a cascade of molecular events 
capable of causing remodeling and repair of the dermal matrix for skin contour 
irregularities. In some indications it is reported to increase type-I collagen (Karimipour, 
Karimipour, & Orringer, 2010).  It has proven effectiveness in skin conditions including 
acne scars, mottled pigmentation and fine wrinkles.  Only a very limited number of 
studies have evaluated the use of microdermabrasion for treatment of SD, none with 
significant results. Karimipour et al. (2010) concluded that the use of microdermabrasion 
for SD was less effective than glycolic acid and chemical peels. Some reports suggest this 
technique may have a greater effect on striae alba than striae rubra (Elsaie, et al, 2009). 
Surgery is an option meant to remove or relocate striae but has significant 
potential toxicity and cost (Baroudi, 1979).  Subcision is a surgical technique utilized to 
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manage depressed scars.  Its goal is to sever the fibrous attachments beneath the scar at 
the subdermal level in order to lift up the scar and induce the formation of connective 
tissues through normal physiological healing (Alsufyani & Alsufyani, 2012). A pilot 
study to determine if subcision is an effective treatment option for striae, showed a high 
percentage of striae treated in this manner developing necrosis (Luis-Montoya, Pichardo-
Velázquez, Hojyo-Tomoka, & Domínguez-Cherit, 2005).   
As evident from the information presented, a wide variety of treatments have been 
evaluated as treatment modalities for SD, however none has shown consistent results and 
thus there is no ‘gold standard’ treatment for improving the pathology of striae. This 
underscores the need to develop an effective and safe intervention that will modulate the 
wound healing process after striae scar development. A novel potential treatment, topical 
application of Pirfenidone, holds great promise in this indication. 
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PIRFENIDONE 
 
Because established treatment modalities for SD have been determined 
inconsistent or ineffective, we propose the use of KitosCell, a topical application of 
Pirfenidone, as an effective and safe treatment for SD. Pirfenidone (PFD) [5-methyl-1-
phenyl-2-(1H)-pyridone] (Figure 1) is a small molecule that has been shown to modulate 
the wound healing process and scar formation by regulating the action of a series of 
cellular factors. PFD is a white, odorless microcrystalline solid with a strong bitter taste. 
PFD is highly soluble in ethyl alcohol, chloroform, various lipid oils, and other lipid 
solvents, thus it is easily formulated to move through cell membranes (Macías-Barragán 
et al., 2010). Its characterization is well known by spectroscopic techniques such as gas 
chromatography, high-performance liquid chromatography (HPLC), infrared 
spectroscopy and magnetic resonance imaging.  
IUPAC Name: 5-methyl-1-phenyl-2-(1H)-pyridone 
 
Molecular Weight 185.22184 [g/mol] 
Molecular Formula C12H11NO 
XLogP3-AA 1.9 
H-Bond Donor 0 
H-Bond Acceptor 1 
Rotatable Bond Count 1 
Exact Mass 185.084064 
Mono Isotopic Mass 185.084064 
Topological Polar Surface Area 20.3 
Heavy Atom Count 14 
Formal Charge 0 
Isotope Atom Count 0 
 
Figure 1. Structural formula and information on Pirfenidone. 
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Pharmacokinetic experiments in humans show a good safety profile with low 
toxicity. The acute toxicity and pharmacodynamics properties of PFD have been reported 
in multiple in vitro and in vivo animal studies. In addition, evidence from numerous 
published studies shows that PFD can modulate tissue remodeling and collagen 
metabolism. Data from published studies suggest that PFD may: (1) modulate tissue 
remodeling of fibrotic lesions, (2) remodel pre-existing abnormal lesions, and (3) prevent 
the formation of abnormal wound lesions following injury. Because of PFD’s 
documented low toxicity and its ability to modulate molecular effects involved in the 
wound healing mechanism, application of KitosCell shows great promise as a novel 
therapeutic treatment for SD. 
 
Molecular Mechanisms for Cytokine Signal Regulation 
Although knowledge of PFD is growing, its precise mechanism of action has yet 
to be clearly defined. Experiments evaluating PFD use in different pathological 
phenotypes have revealed clues of its actions in the wound healing process and have 
helped to broaden understanding of PFD’s molecular mechanism of action. Through 
various experiments, PFD has been determined to regulate wound repair by influencing 
cytokine signaling of growth factors including TGF-βs, connective tissue growth factor 
(CTGF), PDGF, and TNF-α, all important players in the wound healing process (Zhong, 
Sun, Lin, Wu, & Yu, 2011). Modulation of these signaling pathways can lead to changes 
in cellular function, including changes in collagen metabolism and inflammatory 
response. How PFD modulates cytokine signaling is the focus of current research, but 
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evidence that PFD can modulate transcriptional activity has been discovered. Whether 
cytokine signaling is influenced at a pre-transcriptional level is still debatable, but data 
collected from different experimental observations has helped to develop a more putative 
knowledge of the action of PFD. 
 
TGF-β 
PFD has been shown to modulate the activity of TGF-βs involved in collagen 
metabolism. A great deal of evidence suggests that TGF-βs is a central regulator of 
fibrosis. Several animal models over expressing the TGF-β family of cytokines have 
shown extensive progressive fibrosis, indicating that TGF-βs may play a predominant 
role in the progression of pulmonary fibrosis. Enhanced TGF-β gene expression in 
models of pulmonary fibrosis correlates with increased collagen and protein deposition. 
Likewise, human fibrotic lung tissue shows enhanced TGF-β gene and protein 
expression. The use of TGF-β antibodies resulted in the reduction of collagen deposition 
in murine bleomycin-induced lung fibrosis. Therapeutic efforts are therefore focusing on 
inhibition of TGF-β activities in indications with excessive fibrotic deposition. PFD 
modulates TGF-β gene expression and subsequent activity in vivo resulting in inhibition 
of TGF-β-mediated collagen synthesis. In bleomycin-induced lung injury hamster model 
PFD treatment resulted in the decrease TGF-β gene expression by 33% (S N Iyer, 
Gurujeyalakshmi, & Giri, 1999). For idiopathic pulmonary fibrosis (IPF) patients, PFD 
appears to slow progression of the disease process. In numerous other animal and human 
trials PDF has been shown to modulate the fibrotic composition at injury sites. 
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TNF-α 
PFD has also been studied in multiple Phase 1, Phase 2 and Phase 3 clinical trials 
for its abilities to inhibit the synthesis and activity of tumor necrosis factor-alpha (TNF-
α). Inhibition of TNF-α activity can eliminate edema, or vesicant responses (vesicles or 
blisters) caused by repeated trauma injury, injury caused by scalding or burns, skin injury 
caused by chemicals, products released by microbial infection (e.g. endotoxin), 
immunologic response to contact with a foreign biological product (e.g. contact 
dermatitis, insect bite), as well as classical allergic response and radiation exposure (e.g. 
sunburn). In each of these conditions, the initiating and dominating pathophysiologic 
action is directly a result of an immediate local release and/or synthesis of massive 
amounts of TNF-α from several types of cells at or adjacent to the injury site. The locally 
released TNF-α is followed by additional synthesis and release of TNF-α by invading 
macrophages drawn to the injury site by a cascade of chemotactic cytokines released 
locally from cells triggered by the greatly elevated TNF-α concentrations. PFD has been 
found to inhibit the synthesis of TNF-α or block the pathophysiological effects of TNF-α 
at injury sites. By inhibiting or blocking the synthesis, release, and the pathophysiologic 
actions of excessive levels of TNF-α, PFD indirectly inhibits the release of other 
biochemical products from cells such as histamines, prostaglandins, bradykinins, and 
peroxidases which can facilitate the arrest or resolution of the tissue or organ damage and 
aid in enabling the restoration of normal cellular function. 
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NF-κB 
The ability of PFD to block the actions of several key cytokines suggests that it 
acts within the cell at a common molecular level within the nucleus. Iyer et al. (1999) 
demonstrated  these actions occur at the pre-transcriptional level where an interface 
occurs between signals from specific genes or groups of genes. At this level, cellular 
responses to stimuli, such as injury, are transmitted to the transcription process by nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-ĸB)-related proteins 
(Nakanishi et al., 2004). Almost every tissue depends upon these NF-ĸB proteins to 
initiate and influence the transcription process. These transmissions regulate:  
1) mitotic events and exert control via the cyclins, 
2) signals from genes which influence the transcription process and thereby 
implement 
a. the numerous biochemical synthetic processes which are normal for 
homeostatic (physiologic and biochemical) maintenance of the cytoplasm 
as well as nucleus of the cell, 
b. the synthesis and/or storage of a spectrum of biochemicals which are 
externalized by secretion from the cell so as to complement or regulate 
other cells in the adjacent environment; 
3) regulate apoptosis or necrosis of cells and tissues,  
4) regulate immunologic response of cells-type associated with synthesis or storage 
of antibodies to foreign substances or in generation of "autoimmunity" 
(Hoffmann, Natoli, & Ghosh, 2006). 
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Cytokines act as monitors of events connected with cellular injury and result in 
orchestrating the cellular proliferation and biochemical processes required to repair 
damaged cells or tissues. During normal tissue repair, the NF-ĸB related proteins are the 
common pathways of many of these cytokine signals. When excessive amounts of these 
cytokines are generated at the sites of injury, large amounts of the NF-ĸB related 
transcriptional proteins are synthesized and released. If the elevated NF-ĸB levels are not 
rapidly reduced to normal levels, adverse events may follow. 
Results from Nakanishi et al. (2004) describe the effects of PFD on NF-κB 
activity. In transfection experiments of cultured hepatocytes, a decreased transcriptional 
activation of inducible nitric oxide synthase (iNOS), a cellular signal for nitric oxide 
production, was exhibited in transfection experiments. Results also indicated that PFD 
inhibited transcriptional activation of the iNOS gene promoter, but had no effect on its 
nuclear translocation (Nakanishi et al., 2004). These observations support the hypothesis 
that the action of PFD must involve the NF-ĸB proteins since PFD repeatedly has shown 
a powerful inhibiting action against major cytokines, such as TNF-α and TGF-β.  
Given the critical importance of these growth factors and their downstream 
signaling pathways, targeting TNF-α and TGF-β may lead to alterations in the scar 
formation of patients with SD. Topical administration of PFD has the potential to alter 
the disproportionate synthesis and degradation of matrix proteins in SD. 
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Pharmacokinetics of PFD in Human and Animal Models 
Pharmacokinetic parameters of PFD have been explored in numerous animal and 
human studies. Shi et al. (2007) designed a study to evaluate the pharmacokinetics of 
single escalating doses and multiple oral doses of PFD in healthy patients. A total of 48 
subjects were included in the study and randomized into groups for the dose-escalation (n 
= 12, 6 women and 6 men in each group). PFD was rapidly absorbed through the stomach 
and cleared from plasma following single oral doses. The maximum plasma 
concentrations occurred at 0.33 to 1 hour after administration. The pharmacokinetic 
parameters of the multiple doses were similar to those from single doses under fed 
conditions, indicating no significant accumulation of PFD with repeated dosing. All 
participants tolerated the drug doses well, completed the study and there were no 
significant pharmacokinetic differences found between genders. All participants 
completed the study without serious adverse events, requiring intervention, the most 
frequent being dizziness and nausea. It was also determined that the consumption of food 
significantly affected the absorption of PFD, helping to improve tolerability and reduce 
adverse events incidence. 
To investigate the modulatory effects of PFD in the wound healing process of 
glaucoma and pharmacokinetics of topical PFD application, Sun et al. (2011) instilled a 
PFD solution (0.5%) into a rabbit model’s conjuctival sac. After administration the 
rabbits were sacrificed and the concentrations of PFD from the conjunctive, sclera, 
cornea, aqueous humor, and vitreous were quantified by HPLC. The rapid absorption was 
followed by fast clearance. The maximum concentration was achieved in all the ocular 
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tissues within 20 minutes. Sun et al. concluded that topical administration of PFD might 
be an effective approach to modulating wound healing after glaucoma surgery due to the 
inhibition of fibrotic accumulation in rabbit eyes. 
In a sheep model, Bruss et al. (2008) administered a 30 mg/kg intravenous (IV) 
dose of PFD to observe the plasma clearance of PFD. Four sheep received C14-
pirfenidone; plasma and urine samples were collected from all subjects (n = 6). Once in 
the blood stream PFD is converted to its main metabolite, hydroxypirfenidone (OH-
PFD). However the collection of additional metabolites and conjugated metabolites make 
the liver the most probable site of metabolism. Overall, PFD, OH-PFD, OH-PFD 
glucuronide, carboxypirfenidone, and acetoxypirfendone were discovered from urine 
samples. Results confirmed that PFD and its metabolites disappear with first order 
kinetics with a clearance of 1.2 l/kg/h, half-life of 24 minutes, and distribution volume of 
0.71 l/kg. Organ distributions after 48 hours of IV administration were as follows, in 
descending order of presence: lung, kidney, brain, liver, lymph node, and adipose tissue, 
consistent with wide distribution in higher irrigated organs. Urine samples contained 
approximately 80% of tracer, of this less than 1% was in the form of the parent drug and 
50% was in the form of identifiable PFD metabolites. Therefore, PFD was shown to be 
rapidly absorbed and completely metabolized in animal model studies. 
Similarly, Braim et al. (2008) administered a single dose of PFD intravenously to 
horses to investigate plasma pharmacokinetics of PFD and major metabolites and 
temporal effects of PFD infusions. Mild clinical effects, including tachycardia and 
muscle fasciculation, were observed during drug administration, yet stopped at the end of 
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infusion. No additional adverse events were noted after the termination of infusion. PFD 
metabolites were detected 5 minutes after infusion and no parent drug or metabolites 
were detected after 24 hours in the plasma. Ultimately, only transient adverse events were 
noted during the administration and drug metabolism, with rapid clearance. 
In summary, PFD has a simple chemical structure that is soluble in alcohol and 
chloroform allowing it to easily translocate through the cell membrane without requiring 
a membrane-bound receptor. When administered orally, it is absorbed readily in the 
gastrointestinal tract and reaches the blood stream rapidly. After topical application in the 
rabbit eye, ocular tissues absorbed PFD within 20 minutes. After IV infusion, the half-life 
this drug was calculated to be 24 minutes. PFD was shown to rapidly diminish in plasma 
concentration and accumulate in tissues with a higher concentration in more irrigated 
organs. Complete metabolism was accomplished, most likely in the liver, to a variety of 
metabolites and finally eliminated through the kidney in the urine. In samples of sheep 
urine, it started to appear after 48 hours. Due to these results, application of PFD in a 
topical form for SD appears to be safe and submit patients to low toxicity. 
 
Use of PFD for Fibrotic Diseases in Humans 
PFD has been shown to regulate key growth factors and fibrotic cytokines when 
tested in animal and clinical trials to evaluate its effects on inflammation and fibrosis. It 
has shown a pharmacologic ability to treat excessive collagen formation in hypertrophic 
scars and in removing or preventing scar tissue found in fibrosis associated with injured 
tissues or various organs (skin, lung and liver) (Schaefer, Ruhrmund, Pan, Seiwert, & 
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Kossen, 2011).  All of these diseases share a pathological irregularity in which collagen 
deposition exceeds its degradation. 
 
Skin 
Hypertrophic and keloid scars result from a regeneration-regulating mechanism 
gone awry in the wound healing process. They are characterized by an excessive 
formation of fibrous scar tissue at the wound site. This collagen overproduction can be 
attributed to a strong proliferating activity of the fibroblasts. The cytokine signaling 
related to keloid and hypertrophic scar formation is still being investigated, however 
recent studies are focusing on the influence of various growth factors such as TGF-β and 
PDGF. These growth factors have been shown to be overexpressed in keloid formations 
(Wolfram, Tzankov, Pülzl, & Piza-Katzer, 2009). Patients also have pruritus, pain, or 
pressure in addition to the fibrous growths. Adding to their complexity, treatment is often 
stifled by disfiguration during treatment and frequent recurrence. 
Armendariz-Borunda et al. ( 2012) evaluated the efficacy and safety of 
KitosCell® (topical PFD), 8% in pediatric patients with hypertrophic scars caused by 
burns of different etiologies. Pediatric patients with hypertrophic scars between the ages 
of 3 to 16 years of age were enrolled in this trial.  Thirty-three patients were enrolled in 
the study group to receive the pirfenidone treatment and 30 patients were enrolled in the 
control group to receive pressure therapy. From the first month of treatment, patients in 
the PFD group showed statically significant scar regression in comparison with their 
initial Vancouver score measurement (P ≤ 0.001). This was continuous and progressive 
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until the 6th month of treatment. When comparing the two groups, the PFD group 
experienced significantly higher improvement in the Vancouver Scar Scale (VSS) and 
Visual Analog Scale (VAS) scores at every month’s determination. At the end of the 6 
months, the PFD group had significantly higher improvement than the pressure therapy 
treatment group (P ≤ 0.001). In the PFD group, 9 of 33 patients (27%) showed a 
decreased in their VSS scare of more than 55%, 22 patients (67%) decreased it from 30% 
to 45%, and only 2 patients had a 30% decrease or less in their VSS score.  Patients in the 
control group showed a slight improvement of 16% on the average (P=0.001). It was 
concluded that topical administration of 8% PFD gel 3 times a day is more effective and 
safe in comparison to standard pressure therapy for the treatment of hypertrophic scars 
caused by burns in pediatric population. Only minor adverse events such as rash and local 
erythema were reported.  
 
Lung 
The effects of PFD to treat pulmonary fibrosis has been evaluated in interstitial 
pulmonary disease, lung fibrosis resulting from bleomycin, and several other types of 
acute lung injury (Macías-Barragán et al., 2010). Interstitial pulmonary diseases have 
many different etiologies and encompass many pathological processes, yet all affect the 
pulmonary interstitium. This group of disorders is characterized by deep scarring of the 
lung, resulting in shortness of breath and ultimately death if no effective intervention is 
determined. 
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The most common form of interstitial pulmonary disease, IPF, poses a significant 
management challenge to patients and health care professionals. The natural progression 
of IPF is fatal, secondary to respiratory failure (Azuma, 2012). Conventional anti-
inflammatory treatment, involving corticosteroids and some immunosuppressants, 
focuses on suppressing inflammation within pulmonary tissues and is effective in 
delaying disease progression in 23% of cases. For patients who have struggled with IPF 
for extended periods of time and are past the initial inflammatory stage of the disease, an 
agent to modulate the fibrotic deposition in interstitial tissue was hypothesized to be a 
more effective form of treatment.  
The tolerability and efficacy of PFD was evaluated for the first time in a clinical 
setting by Raghu et al. (1999) in terminally ill patients with advanced IPF. The study 
enrolled late-stage IPF patients, regardless of illness or physical limitations. Enrolled 
patients had exhibited progressive deterioration or not tolerated conventional therapy 
prior to study enrollment. Fifty-four patients participated in the study and were followed 
for mortality, change in lung function, and adverse events. The drug was well tolerated in 
patients who reported non-threatening adverse events due to treatment, but these subsided 
after a decreased dose or discontinuation of PFD. After treatment, 38 of 46 patients were 
able to suspend conventional treatment of prednisolone within two months of study 
enrollment. Eight were able to reduce their daily prednisolone dose and 8 had no 
conventional treatment to begin with. The 1- and 2-year survival rates were 78% and 
63%, respectively.  
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Because the study enrolled a small number patients with significant co-
morbidities, lacked randomization and controls, and had inconsistent historical data, there 
was insufficient data to substantiate the efficacy of PFD as a treatment for IPF. However, 
the study results are still promising. In addition to the absence of serious adverse events, 
PFD did not result in blood count or blood chemistry abnormalities.  Pulmonary function 
test (PFTs) measurements stabilized following PFD treatment. An inhibition in the 
decline of forced vital capacity (FVC)/vital capacity (VC) was seen after administration 
leading researchers to believe that the results may correlate with a decrease in mortality 
rate. 
In 2005 Azuma et al. published results of a double-blind, placebo-controlled, 
randomized, prospective clinical trial to evaluate the efficacy and safety of PFD in adult 
patients with IPF. A total of 109 patients were enrolled in this study and randomly 
assigned either to PFD or placebo treatment arms in a 2:1 ratio. Twenty-five different 
clinics in Japan participated in the trial and enrolled subjects who demonstrated adequate 
oxygenation at rest and oxygen saturation (SpO2) of 90% or less during exertion while 
breathing air within 1 month before enrollment. The primary endpoint was defined as the 
change in the lowest SpO2 by pulse oximetry during a 6-minute steady-state exercise test 
(6MET), secondary endpoints were changes in resting PFTs while breathing air, disease 
progression by high-resolution computerized tomography (HRCT) patterns, episodes of 
acute exacerbations if IPF, changes in serum markers of pneumocyte damage, and 
changes in quality of life measurements. This study demonstrated no difference in 
primary endpoint results but a significant difference in secondary endpoints including  
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change in VC and acute exacerbation incidence after 9 months of treatment. Whereas 
there was no significant difference in the primary endpoint between the two groups when 
the data were analyzed for all patients, a positive trend was noted after 9 months of 
treatment in the PFD group. However, PFD treatment suppressed the decrease in 
oxygenation during exercise in a subset of patients who did not demonstrate SpO2 less 
than 80% during baseline assessment. During the 9-month follow-up study, the most 
important findings noted were that the episodes of acute exacerbation of IPF manifested 
exclusively in the placebo group and there was a lesser decline of  change in VC in 
patients receiving PFD (Azuma et al., 2005).  
 Taniguchi et al. (2010) developed a study after obtaining encouraging results 
from the previous Phase II clinical trial. The objective of this trial was to further 
investigate the therapeutic effects and safety of oral PFD on lung functional deterioration 
and disease progression in IPF patients. The aim of this study was to determine the 
change from baseline VC when compared to placebo. Results indicated that those treated 
with PFD improved VC, and the distribution of progression-free survival was better than 
in the placebo group. 
Oral PFD is approved for marketing in 29 European countries and Canada under 
the InterMune trade name Esbriet® for IPF and in Japan and South Korea where it is 
marketed by Shionogi & Co. Ltd under the trade name Pirespa®. Under different trade 
names, PFD is also approved for the treatment of IPF in China, India, and Argentina. 
PFD has been granted Orphan Drug and Fast Track designation by the Food and Drug 
Administration (FDA), and also has been granted Orphan Drug status in Europe. 
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InterMune is currently conducting an additional Phase III study, ASCEND, in the United 
States to confirm the efficacy of PFD and support the regulatory registration of Esbriet® 
for the treatment of IPF.  
Before the introduction of PFD, the prognosis of patients suffering from IPF was 
grim. The fatal progression and lack of effective treatments for this disease presented a 
management challenge to clinicians and patients. Because of the immuno-modulatory and 
anti-inflammatory properties of PFD, researchers hoped that it could fill the unmet 
medical need of patients with IPF. In numerous studies of PFD treatment for IPF, the 
drug has a well-documented track record of safety. No significant adverse events and 
only transient adverse events which subsided after cessation or dose modification, were 
documented during studies. PFD has documented success in slowing the decline in lung 
function, slowing the accumulation of scar tissue, and shows great promise as a safe, well 
tolerated treatment for IPF.  
 
Liver 
Liver fibrosis occurs in many different types of liver diseases. It is a consequence 
of collagen and ECM protein accumulation in response to liver injury. Hepatic stellate 
cells (HSC) are activated by fibrogenic cytokines such as TFG-βs, angiotensin II, and 
leptin to change to a myofibroblast-like phenotype (Bataller & Brenner, 2005). These 
activated cells have been identified as major collagen-producing cells in patients with 
liver fibrosis. Advanced liver fibrosis can be the result of a variety of etiologies.  
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Due to the high collagen deposition in effected liver pathology, the use of 
antifibrotic therapies has been explored to inhibit or prevent the formation of ECM 
proteins. A pilot study to evaluate the safety and efficacy of PFD in 15 patients with 
established liver disease caused by hepatitis C virus chronic infections was performed by 
Armendariz-Borunda and colleagues (2006). Color Doppler biopsies obtained at baseline 
and after 12 months of treatment showed improvements in the following liver histology: 
necrosis, inflammation, steatosis, fibrosis, and cell regeneration to pathologists who were 
blinded to the sequence and clinical biochemical characteristics of the patients. Gene 
expression of key molecules involved in collagen turnover was quantified using real time 
polymerase chain reaction. Similarly, mRNAs coding for profibrogenic molecules such 
as collagen, type I, alpha 1 (Col1A1), TGF-β and TIMP-1 were markedly down-regulated 
at the end of treatment. 
 
PFD has shown evidence of benefit in a wide variety of fibrotic diseases where it 
has been shown to modulate fibrotic deposition. Most clinical trials describe that PFD is 
generally well tolerated with mild adverse events. The most common adverse effects 
include gastrointestinal discomfort, anorexia, fatigue, sedation, and photosensitivity rash. 
Often these symptoms are temporary and resolve completely once the drug is withdrawn. 
Overall, the results from multiple pilot studies of PFD in the treatment of other 
indications provides a significant rationale that PFD appears to be safe in a variety of 
patient populations and provides an effective means of altering the cytokine-mediated 
processes involved with fibrosis. PFD may also show evidence of benefit to patients of 
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many fibrosis-related diseases, such as multiple sclerosis (MS), Harmansk-Pudlak 
syndrome, focal segmental glomerulosclerosis, idiopathic pulmonary fibrosis (IPF), 
hypertrophic cardiomyopathy, kidney disease in patients with diabetes, neurofibromatosis 
type 1, plexiform neurofibrosis, and fibrosis caused by radiation therapy for cancer 
(Macías-Barragán et al., 2010). Although pathological manifestation of fibrotic disorders 
and SD is dichotomous, the pathway in their formation shares many of the same 
elements. The cytokines and downstream pathways that regulate mechanisms resulting in 
excessive fibrosis are the same pathways that lead to a loose ECM and low collagen 
deposition in SD. Thus, PFD may prove to be a safe and effective treatment for SD.   
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PROPOSED CLINICAL TRIAL PROTOCOL 
 
 
 
 
Recruitment 
Placebo TID with 
monthly evaluations 
(mo 1-6) 
KitosCell TID with 
monthly evaluations  
(mo 1-6) 
Primary Endpoint 
Determine safety and efficacy of Pirfenidone, 8% 
topical gel composition (KitosCell®) as 
treatment for steroid induced striae. 
 
Randomize 
Select treatment area 
Optional:  KitosCell 
TID with monthly 
evaluations (mo 6-12) 
 
7.5 x 7.5 cm. area with at 
least one striae defined as 
Region of Interest (ROI) 
Study Assessment (12 mo) 
Study Assessment (6 mo) 
Course #1 
Course #2 
Figure 2: Protocol Schema. 
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Table 1. Study Time and Events Table. 
  
KitosCell/Placebo 
Treatment 
Optional KitosCell 
Treatment1 
 
Baseline
2
 
Course #1 
(mo 1-6)
2
 
Study 
Assessment 
(6 mo) 
Course #2 
(mo 6-12) 
Study 
Assessment 
(12 mo) 
Patient Registration X     
Clinical Assessment X X X X X 
Biopsy
3
 X  X  X 
Photographic Assessment X X X X X 
Laboratory Studies 
(CDC/differential) 
X  X  X 
Visual Analog Scale (VAS)  X X X X X 
Vancouver Scar Scale (VSS) 
(Expert dermatologist review 
of photographs) 
X X X X X 
Patient Assessment Scale 
(POSAS)(Investigator and 
patient review) 
X X X X X 
Adverse Event Inventory  X X X X 
Case Report Forms/Data 
Collection 
X X X X X 
 
1 
KitosCell Treatment offered to patients regardless of initial treatment. 
2 Course #1 Treatment can start same day as Baseline assessment with 
confirmation of patient eligibility. 
3 
Second biopsy will be obtained at completion of treatment, either at the 
completion of 6 months of treatment, or at the completion of 1 year of treatment 
(not both). 
 
1.0 Objective 
The overall objective of this proposed study is to evaluate the safety and efficacy 
of Pirfenidone, 8% topical gel composition (KitosCell®) in the resolution of striae 
distensae.  
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2.0 Hypothesis 
KitosCell® can be efficiently and safely administered as a topical gel to steroid 
induced dermatologic striae  and will lead to healing of the skin lesions as measured by 
minimized color and diminished size of the striae.  
 
3.0 Patient Selection  
All trial patients must meet the following inclusion and exclusion criteria.   
3.1 Inclusion Criteria  
3.1.1 Patient is at least 12 years old. 
3.1.2 Patient has diagnosis of striae. 
3.1.3 Patient has completed active oncologic treatment (chemotherapy and/or 
radiation) for greater than 6 months. 
3.1.4  Patient is not neutropenic (must have  Absolute Neutrophil Count ≥ 
1,000/µl) 
3.1.5 Patient or guardian has signed informed consent according to institutional 
guidelines.  
3.2 Exclusion Criteria 
3.2.1 Patient does not have underlying genetic connective tissue disorder that 
increases the risk for striae (such as rheumatoid arthritis, Marfan 
syndrome, lupus erythematous, scleroderma or similar disorders). 
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3.2.2 Patient does not use immunosuppressive drugs (including systemic 
corticosteroids, unless being used for acute symptoms (i.e. asthma 
exacerbation).   
3.2.3 Patient does not have diagnosis of immunodeficiency.  
3.2.4 Patient does not have active dermatologic infections in area to be treated 
for study. 
3.2.5 Patient is not pregnant or breast-feeding. Female patients of childbearing 
age must have negative serum or urine pregnancy test within 1 week prior 
to enrollment. 
 
4.0 Registration and Pretreatment Procedures 
This is a blinded, placebo controlled trial. Clinical site personnel will determine 
eligibility of prospective subjects. Eligible patients must be registered prior to treatment 
to verify eligibility and obtain the dose assignment. When a patient has signed informed 
consent, then the Eligibility Checklist form should be sent to study sponsor. The patient 
will be assigned a case number and randomized to receive KitosCell study drug (topical 
pirfenidone) or placebo. Following registration, subjects may begin protocol treatment.  
 
4.1 Registration Process 
4.1.1 Obtain written informed consent from the subject/guardian/parent prior to 
performing any study specific assessments. 
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4.1.2 Confirm eligibility of patient (subject must meet each inclusion and 
exclusion criteria list in protocol). 
4.1.3 Submit the supporting documentation (laboratory report, History and 
physical results, met eligibility criteria) and the consent to study sponsor. 
4.1.4 Study sponsor will verify eligibility, register the subject on the study, 
assign a protocol case number, and be randomized  to receive study drug 
(pirfenidone) or placebo.  
4.2 Pretreatment Evaluation 
The following should be performed as the pre-treatment assessment: 
4.2.1 History and physical examination. 
4.2.2 Obtain baseline laboratory studies (complete blood count and differential; 
urine/serum pregnancy test if indicated). 
4.2.3 Obtain baseline digital photographs (3) of ROI. 
4.2.4 Completion of Patient Assessment Scale (POSAS) by the subjects. 
 
5.0  Treatment Plan 
5.1 Overview  
 Eligible patients will be randomized to receive KitosCell (topical 
pirfenidone) or placebo.  
 Patients will undergo a pre-assessment visit including physical 
examination and laboratory evaluation.  
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  Prior to treatment, the patient will have baseline photographs taken of 
striae and a region of interest (ROI) will be defined (measured and 
mapped).  
 Patients will be instructed how to measure dose of study drug/placebo, 
how to apply it to ROI, and the frequency of application. The treatment 
area for each patient will be the same dimensions, but may vary with 
regard to where on the body the ROI is located. Patients will apply daily 
doses of study drug/placebo and return at one month intervals for physical 
examinations and repeat photographs of ROI.  
After 6 months of treatment, the following parameters will be evaluated: 
photographs of ROI, laboratory studies (complete blood count and 
differential), Investigator Assessment (VAS and VSS), Patient Assessment 
Scale (POSAS) and Adverse Event Inventory. At this point patients will 
be given the option to stop treatment. 
OPTIONAL:  
1. If patients opt to continue treatment beyond 6 months, they will 
receive study drug (KitosCell) regardless of which group—study drug 
or placebo—they were randomized to in the first 6 months of 
treatment. Patients will be directed to administer the study drug to the 
ROI in the same manner and frequency for an additional 6 months. 
Monthly physical examinations and pictures of ROI will continue 
during the second 6-month period of treatment. After a full year of 
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treatment is complete, a final assessment will occur with the same 
parameters as at the initial 6-month treatment completion.  
2. Patients will be given the option to have skin biopsies at the beginning 
and at the end of their study treatment. The ‘end of treatment’ is 
defined as either after 6 months of receiving study drug or placebo, or 
after 1 year (if they opted to receive an additional 6 months of 
treatment).  The final biopsy will be obtained within 4 weeks of 
completion of treatment.  Testing that will be collected include:  
a. H&E Stain (to assess the characteristics of skin, epidermal and 
dermal thickness). 
b. Masson Trichrome (to assess collagen and its conformational 
arrangement). 
5.2 KitosCell/Placebo Administration 
Investigators will advise patients how to measure and administer 
KitosCell/placebo gel. 
 
6.0  Patient Assessments 
6.1 Evaluation During and After Treatment  
6.1.1 Treatment Assessment 
The following will be performed monthly as patient receives study drug or 
placebo. They should occur every 3-5 weeks from the date of the 
baseline/previous assessment: 
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6.1.1.1 History and physical examination. 
6.1.1.2 Obtain digital photographs (3) of ROI. 
6.1.1.3 Completion of Patient Assessment Scale (POSAS) by the subjects. 
6.1.1.4 Adverse Event Inventory. 
6.1.2 Post-completion of Treatment Evaluation  
The following will be performed at the 6-month completion of treatment of study 
drug and/or placebo, and after one year of treatment if the patient elects to 
continue treatment (optional phase of study). 
6.1.2.1 History and physical examination. 
6.1.2.2 Laboratory studies (complete blood count and differential). 
6.1.2.3 Obtain digital photographs (3) of ROI. 
6.1.2.4 Completion of Patient Assessment Scale (POSAS) by the subjects. 
6.1.2.5 Completion of Investigator Assessment Scale (VSS) by the 
investigators. 
6.1.2.6 Adverse Event Inventory. 
6.1.2.7 Optional: Biopsy at completion of treatment: either after 
completion of 6 months of treatment or after one year of treatment 
(not both) depending upon whether patient opted to continue 
treatment (optional phase of study). 
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6.2 Photographic Documentation of Target Striae: 
Investigators will define an area of skin to be studied/evaluated as the ROI. 
Digital photographs of the treatment area will be taken by the provider using a computer-
controlled digital camera under standardized illumination conditions.  
Three digital photographs will be taken of the ROI with each assessment. 
Investigators will analyze and compare photographs with baseline, measuring striae size, 
area and grading color changes. 
6.2.1 Photographic evaluation 
Standardized photographs will be taken of the region of interest (ROI). A 
measurement scale and color scale card will be included in the photograph in an 
effort to maintain consistency of photos. The ROI will be outlined and the area of 
the most pronounced striae will be calculated. Future assessments should be 
performed in an effort to repeat the baseline photograph. Erythema and melanin 
index (EI and MI) will be calculated using the method described in Yamamoto, et 
al. (2008).  
6.3 Investigator Assessment Scales 
Clinical experts will perform a blinded review to analyze and compare 
photographs obtained at baseline, with those obtained at the completion of Course #1 
and, if applicable, Course #2. Two assessment scales will be utilized to achieve this 
review: Vancouver Scar Scale (VSS) and Visual Analog Scale (VAS). 
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6.3.1. Vancouver Scar Scale (VSS) 
VSS, shown in Table 2, is the most widely used outcome measure in burn and 
similar scarring studies. It assesses 4 variables: vascularity, height/thickness, 
pliability, and pigmentation, using a 0 to 13 scoring system. 
 
Table 2. Vancouver Scar Scale. 
Scar Characteristics Score 
Vascularity 
 
 
 
Normal 0 
Pink 1 
Red 2 
Purple 3 
Pigmentation 
 
 
Normal 0 
Hypopigmentation 1 
Hyperpigmentation 2 
Pliability 
 
 
 
 
 
Normal 0 
Supple 1 
Yielding 2 
Firm 3 
Ropes 4 
Contracture 5 
Height 
 
 
 
Flat 0 
<2 mm 1 
2–5 mm 2 
>5 mm 3 
Total score 13 
 
6.3.2. Visual Analog Scale (VAS) 
The VAS is a photograph-based scale derived from evaluating standardized 
digital photographs in 4 dimensions (pigmentation, vascularity, acceptability, and 
observer comfort). It sums the individual scores to get a single overall score 
ranging from “excellent” to “poor”. It has demonstrated high observer reliability 
and internal consistency when compared to expert panel evaluation. 
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6.4 Patient and Observer Scar Assessment Scale (POSAS) 
Patients and observer will complete a questionnaire during each visit and a score 
will be calculated. The POSAS is a scar assessment scale that includes subjective 
symptoms of pain and pruritus with an expansion on the objective data captured in the 
VSS. It consists of two numerical scales: the Patient Scar Assessment Scale and the 
Observer Scar Assessment Scale, utilizing a scoring system from 5-50. It assesses 
vascularity, pigmentation, thickness, relief, pliability, and surface area, and it 
incorporates patient assessments of pain, itching, color, stiffness, thickness, and relief. 
6.5 Measurements and Evaluations to be Obtained  
Assessments will be obtained according to the timeline presented in Table 1. 
 
7.0 Off-Study Criteria 
Patients can be withdrawn from the study for the following reasons: 
 Patient or family withdraws consent. 
 Removal from protocol therapy by the principal investigator if patient unwilling 
or able to comply with protocol requirements. 
 
8.0 Ethical and Regulatory Considerations 
8.1 Consent Procedure 
All patients and/or their parents or legal guardians must sign an approved 
informed consent form in order to be eligible for this study. 
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8.2 Confidentiality 
Confidentiality of patients’ records will be maintained within legal limits. The 
data from this study may be published; however no patients will be named or identified. 
A list of patients and their randomization results (receiving study drug or placebo) will be 
kept locked at study sponsor location. 
8.3 Risk-Benefit Ratio 
The present study may have no benefit to the study subjects. Previous oral and 
topical studies of pirfenidone demonstrate improvements of scarring similar to striae. 
Clinical and non-clinical data has shown its efficacy in the treatment of hypertrophic 
scarring and chronic ulcers. Important information will be gained regarding the efficacy 
of pirfenidone for treatment of striae. 
8.4 Adverse Event Reporting 
Adverse events should be reported to the study sponsor. Adverse Events will be 
monitored and graded according to the Common Terminology Criteria for Adverse 
Events Version 3.0 (CTCAEv3.0). Adverse events not included in the CTCAEv3.0 
should be reported and graded under the Other adverse event within the appropriate 
category.  
Adverse events, which are unexpected and associated with the use of this product, 
will be reported to the FDA and the National Institutes of Health (NIH) Office of 
Biotechnical Activities (OBA) according to the schedule shown below in Table 3: 
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Table 3. Adverse Event Reporting Schedule. 
Type of Event Timing of Report  
(relative to when the person responsible 
for making the report becomes aware of 
the event) 
Fatal or life-threatening As soon as possible, no later than 7 
calendar days 
Serious adverse event resulting in one of the 
following:  
1. Inpatient hospitalization  
2. A persistent or significant disability 
or incapacity 
3. A congenital anomaly or birth defect 
4. Important medical event that, based 
on the medical judgment of the 
investigator, may require medical or 
surgical intervention to prevent one 
of the outcomes listed above 
As soon as possible, no later than 15 
calendar days 
Any other unexpected adverse experience 
associated with the use of the product 
In the annual report 
 
Reporting to the IRBs and IBCs will be done according to the requirements of the 
relevant IRBs and IBCs. 
8.4.1 Definition of Adverse Events (AE’s) 
Adverse events (AE’s) will be defined as any treatment related toxicity(s).  
In other studies utilizing topical pirfenidone (Armendariz-Borunda et al., 2012; 
Cell Therapy and Technology, 2008) the most common side effects noted were 
transient, mild pruritis and erythema. 
8.5 Risks 
The risk to health care workers and close contacts is extremely low, so no 
additional precautions are indicated. 
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9.0 Statistical Analysis 
Statistical comparison between study arms will be assessed using Student’s t-test 
following confirmation of normality of the sample distribution. Statistical significance 
will be considered P < 0.05. 
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CONCLUSION 
 
SD affects a substantial proportion of the global population. Although SD is not 
usually an impairing medical problem, it can cause significant psychological distress and 
decrease quality of life. Diverse varieties of treatments have been proposed for SD, 
including diet and exercise, pharmaceutical agent, and laser treatments. However these 
treatments have yielded inconsistent and limited results. In the absence of successful 
treatment option, the goal of this study is to demonstrate that topical PFD can diminish 
the color and size of SD for affected patients. PFD is a small non-peptide with its ability 
to modulate the cytokines and downstream pathways that are responsible for 
inflammation and fibrosis. PFD offers a new hope in the management of SD which 
currently only has limited treatment options. 
Clinical and non-clinical studies have shown that PFD can modulate the wound 
healing process through and is generally well tolerated with minimal adverse effects. 
Possibly related effects noted were mild or transient, and included pruritus, 
desquamation, erythema and/or rash; all resolved independently after treatment cessation. 
Regulation of TGF-β and TNF-α by PFD has shown significant effects on the reparative 
process in many different diseases. As an oral drug, PFD has been approved for treatment 
of IPF in multiple countries outside of the United States . A randomized, double-blind, 
placebo controlled, Phase III trial of PFD for the treatment of IPF is currently underway 
in the United States. In addition, an 8% topical gel formulation of PFD is approved in 
Mexico and other Latin American countries for the treatment of hypertrophic and keloid 
scars as well as acute burns and wound. Clinical data in hypertrophic and keloid scars 
 53 
indicates PFD is effective in the modulation of collagenase and fibroblast activity, which 
lead to effective collagen remodeling.  
These encouraging results support the evaluation of PFD as an agent to stimulate 
the remodeling of the pathological collagen structure found in SD. KitosCell®, topical 
PFD, has been tested and approved for application three times a day as treatment of pre-
existing scars. The goal of this study is to evaluate the safety and efficacy of this same 
schedule and formulation on patients with SD.  
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